Common questions
Ipamorelin: direct answers
Status, legality, doping, mechanism, and side effects — answered straight and cited.
Is ipamorelin FDA approved?
No. Ipamorelin has never been approved by the FDA, or any regulator, for any indication. Its single Phase 2 trial (postoperative ileus, NCT00672074) missed its primary endpoint [3], no Phase 3 followed, and in 2024 the FDA restricted its compounding access. It is sold only as a research chemical.
Is ipamorelin legal?
Ipamorelin is not a controlled substance, but it is not an approved drug either. It is sold as a "research chemical," not as a medicine, and it has no approved human use. In 2024 the FDA removed ipamorelin acetate from the interim 503A bulk-substances list, narrowing the legitimate compounding-pharmacy route. Legal status varies by country; this is not legal advice.
Is ipamorelin banned by WADA?
Yes. Ipamorelin is prohibited in sport at all times under the WADA Prohibited List category S2, as a growth hormone secretagogue, and it is detectable in urine by accredited anti-doping laboratories [11]. Athletes in tested sport face sanctions for its use. Anti-doping chemists have also cataloged modified black-market analogs of it [9][10].
Why did the FDA restrict ipamorelin compounding?
In September 2024 the nominator withdrew ipamorelin acetate, and the FDA removed it from Category 2 of the interim Section 503A bulk-substances list. The agency reviewed ipamorelin acetate and the free base at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting. The result is that ipamorelin is not an approved bulk substance for compounding, reflecting its lack of approval and limited evidence.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / GHS-R1a receptor to trigger a growth hormone pulse. In its founding characterization it released GH potently in rats and swine without raising ACTH or cortisol even far above its GH ED50, making it the first highly GH-selective secretagogue [1].
What does ipamorelin do for you?
In studies, ipamorelin triggers a discrete pulse of growth hormone via the ghrelin receptor, cleanly — without spiking cortisol or prolactin [1]. Downstream effects on bone growth appear in rodents [4]. Human outcome evidence is limited to one failed trial [3]. Community-reported effects like better sleep and recovery are anecdotal, covered on the effects page.
What is ipamorelin peptide?
The same compound — "ipamorelin peptide" emphasizes that it is a peptide, a short chain of five amino acids (a pentapeptide). Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, formula C38H49N9O5, weight about 711.9 daltons, CAS 170851-70-4. It is wholly synthetic and acts as a selective ghrelin-receptor agonist [1].
What are the risks of ipamorelin?
The honest answer: largely uncharacterized in humans. The one seven-day trial logged no ipamorelin-specific safety signal [3], but there is no long-term human safety database. A related ghrelin-receptor agonist caused dose-dependent heart-muscle damage in 28-day rat dosing [6], and GH-axis stimulation raises theoretical IGF-1/cancer and glucose concerns. Cited detail is on the effects page.
Does ipamorelin reduce belly fat?
No human trial has tested ipamorelin for fat loss. The closest data is a 2024 ferret study where intraperitoneal ipamorelin (1–3 mg/kg) reduced chemotherapy-induced weight loss by about 24% in the delayed phase — a peripheral effect on weight, not a demonstration of belly-fat reduction [5]. Community reports of a leaner look over weeks are anecdotal and confounded by diet and training.
What are the downsides of ipamorelin?
Unapproved status, one failed human trial, and no long-term human safety data [3]. A class-level cardiac signal appears in chronic rodent dosing of a related agonist [6]. Gray-market material is of unverified purity. Reported nuisance effects include facial flushing, water retention, and increased hunger — anecdotal, detailed on the effects page.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product, so it is not being "discontinued" in the usual sense. Its clinical development stopped after the single Phase 2 ileus trial missed its primary endpoint [3]. The closest recent event is the 2024 FDA action removing ipamorelin acetate from the interim 503A bulk-substances list, which narrows legitimate compounding access.
What does CJC-1295 and ipamorelin do?
They are paired to push growth hormone release through two different receptors: ipamorelin via the ghrelin receptor [1], CJC-1295 via the GHRH receptor. The idea is complementary GH stimulation. There is no controlled human trial of the combination for any outcome, so its real-world effect is unproven; the pairing rests on single-agent pharmacology.
Does ipamorelin increase IGF-1?
Not always. In a 15-day rat bone-growth study, ipamorelin raised bone growth rate with no measurable change in total IGF-1 [4], suggesting a partly local, GH-pulse-driven effect. Over longer or combined protocols, sustained GH-axis activation is mechanistically linked to IGF-1 elevation. The answer depends on duration and context, not a simple yes.
How does CJC-1295 ipamorelin work?
Ipamorelin activates the ghrelin / GHS-R1a receptor on pituitary cells to release a GH pulse [1]; CJC-1295, a GHRH analog, works through the separate GHRH receptor. Used together, they stimulate GH by two independent routes. The mechanism is well-defined for each agent individually; the combination has no controlled human outcome trial.
How much CJC-1295 ipamorelin should I take?
There is no evidence-based dose. No controlled human trial has tested the CJC-1295 + ipamorelin combination, so no studied human dose exists [3]. Community subcutaneous protocols circulating online are anecdotal, with no peer-reviewed human dosing basis. This site reports what studies measured and does not provide dosing recommendations.
Does CJC-1295 ipamorelin work?
For the combination, unproven — no controlled human trial has tested it for any endpoint. Each agent reliably triggers GH release in its own pharmacology (ipamorelin in rodents, swine, and one human PK study [2]), but a GH pulse is not a proven outcome. The one ipamorelin efficacy trial that reached a clinical endpoint failed [3].
How to reconstitute CJC-1295 ipamorelin 5mg?
As a general research-handling note, not an instruction: ipamorelin is supplied as a lyophilized powder and reconstituted with bacteriostatic water for laboratory handling, then typically refrigerated because peptides degrade with heat and freeze-thaw. This describes how the material behaves in research supply; it is not a clinical preparation procedure or guidance for human use.
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin had a terminal half-life of about 2 hours after IV dosing, with the GH pulse peaking near 40 minutes [2]. A roughly two-hour half-life means blood levels fall by half about every two hours, so the parent peptide clears within hours. Its short persistence is also why it challenges anti-doping detection [11].
Does ipamorelin make you hungry?
It can. Ipamorelin acts on the ghrelin receptor — the body's natural appetite trigger — so some users report increased hunger in the hours after injection, though described as milder than with GHRP-6 [4]. This is an anecdotal community report consistent with the mechanism, not a measured clinical finding. Detail is on the effects page.
Will I gain weight on ipamorelin?
There is no human outcome trial to answer this. The single Phase 2 trial was a short perioperative study, not a body-weight study [3]. In a 2024 ferret model, ipamorelin reduced chemotherapy-related weight loss [5]. Community reports vary — some describe leaner composition, some increased appetite — all anecdotal and confounded by diet and training.
Does ipamorelin increase appetite?
Plausibly, by mechanism. As a ghrelin-receptor agonist, ipamorelin engages the same pathway the natural hunger hormone uses, and increased appetite is an occasionally reported community effect [4]. A 2026 sports-medicine review notes animal models show metabolic effects but rigorous human safety data are scarce [13]. The appetite effect is anecdotal in humans, not a clinical measurement.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin / GHS-R1a receptor on pituitary somatotrophs to release a discrete growth hormone pulse, without meaningfully raising cortisol or prolactin [1]. In rodents this drives effects such as longitudinal bone growth [4]. Human outcome evidence is limited to one failed trial [3]; everything else is mechanism, animal data, or anecdote.